The recent FDA approval of the IsoPSA blood test may represent a notable advancement in prostate cancer screening and diagnosis. Developed by Cleveland Diagnostics, the in vitro diagnostic instrument ...

Among men with abnormal levels by any criterion (except PSA velocity), 40% to 55% of those who did not develop documented prostate cancer in the interim exhibited subsequent normal values. The authors ...

DEAR DR. ROACH: I am a 68-year old male in good health who exercises regularly, doesn’t take any medications, and doesn’t have a family history of prostate cancer. During my most recent yearly ...

NEW YORK (Reuters Health) - On average, men's levels of prostate-specific antigen (PSA) decrease as their body mass index (BMI) rises, a new study shows. PSA is a marker for prostate cancer risk when ...

Prostate cancer is much more likely to kill if a man’s PSA level rises rapidly before the cancer is even diagnosed, according to a study that suggests a new and far more meaningful way of looking at ...

ATLANTA - Each year, millions of American men get a blood test known as a PSA, or prostate-specific antigen, test as part of their yearly checkup. PSA is a protein produced by the prostate gland. If a ...

Declines in prostate-specific antigen (PSA) level after treatment with the next-generation androgen receptor inhibitor drug enzalutamide predict improved survival rates in men with non-metastatic ...

PSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response; Telomir-1 lowered PSA ...

Prostate cancer was found in 23% of men whose initially abnormal PSA levels fell to below 4 ng/mL. Men whose PSA levels rise above 4 ng/mL—a commonly used threshold for prostate biopsy—but then ...

The PSA test is an imperfect way to screen men for prostate cancer. But until recently, it was seen as the best option available. The test measures the amount of prostate specific antigen, or PSA, in ...